Join
Live feed
·
PRReleasevia Quantisnow
Soligenix Inc. logo

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

ByQuantisnow·Wall Street's wire, on your screen.
SNGX· Soligenix Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SNGX (Soligenix Inc.) and more on Quantisnow.